Recombinant human Jagged1 protein (Fc Chimera Active) (ab108575)
Key features and details
- Expression system: HEK 293 cells
- Purity: > 90% SDS-PAGE
- Endotoxin level: < 0.100 Eu/µg
- Active: Yes
- Tags: Fc tag C-Terminus
- Suitable for: Functional Studies, SDS-PAGE
Description
-
Product name
Recombinant human Jagged1 protein (Fc Chimera Active)
See all Jagged1 proteins and peptides -
Biological activity
Induction of HES in NIH/3T3 cells.
Inhibition of adipogenesis in NIH/3T3 cells.
-
Purity
> 90 % SDS-PAGE.
ab108575 is 0.2µm filtered -
Endotoxin level
< 0.100 Eu/µg -
Expression system
HEK 293 cells -
Accession
-
Protein length
Protein fragment -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Predicted molecular weight
150 kDa including tags -
Amino acids
1 to 1067 -
Tags
Fc tag C-Terminus -
Additional sequence information
Signal peptide and extracellular domain of human Jagged-1 (aa 1-1067) are fused at the C-terminus to the Fc portion of human IgG1.
-
Associated products
-
Related Products
Specifications
Our Abpromise guarantee covers the use of ab108575 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
Functional Studies
SDS-PAGE
-
Form
Liquid -
Additional notes
Working aliquots are stable for up to 3 months when stored at -20°C. Inhibits adipogenesis of mesenchymal stem cells (MSCs). Induces Hes-1 in 3T3L-1 cells. -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Constituent: PBS
0.2µm-filteredThis product is an active protein and may elicit a biological response in vivo, handle with caution.
General Info
-
Alternative names
- AGS
- AHD
- AWS
see all -
Function
Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation (By similarity). Enhances fibroblast growth factor-induced angiogenesis (in vitro). -
Tissue specificity
Widely expressed in adult and fetal tissues. In cervix epithelium expressed in undifferentiated subcolumnar reserve cells and squamous metaplasia. Expression is up-regulated in cervical squamous cell carcinoma. Expressed in bone marrow cell line HS-27a which supports the long-term maintenance of immature progenitor cells. -
Involvement in disease
Defects in JAG1 are the cause of Alagille syndrome type 1 (ALGS1) [MIM:118450]. Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems.
Defects in JAG1 are a cause of tetralogy of Fallot (TOF) [MIM:187500]. TOF is a congenital heart anomaly which consists of pulmonary stenosis, ventricular septal defect, dextroposition of the aorta (aorta is on the right side instead of the left) and hypertrophy of the right ventricle. This condition results in a blue baby at birth due to inadequate oxygenation. Surgical correction is emergent. -
Sequence similarities
Contains 1 DSL domain.
Contains 15 EGF-like domains. -
Developmental stage
Expressed in 32-52 days embryos in the distal cardiac outflow tract and pulmonary artery, major arteries, portal vein, optic vesicle, otocyst, branchial arches, metanephros, pancreas, mesocardium, around the major bronchial branches, and in the neural tube. -
Cellular localization
Membrane. - Information by UniProt
Images
-
Induction of Hes-1 with the treatment of recombinant Human Jagged1-Fc (ab108575).
A mouse preadpipocyte cell line, 3T3L1, was stimulated with 5µg/ml of ab108575 as in indicated time points and each cell lysate was prepared and subjected to western blot by using anti-mouse Hes1 or GAPDH.
M: Marker
Lane 1: ab108575, 0 min
Lane 2: ab108575, 10 min
Lane 3: ab108575, 30 min
Lane 4: ab108575, 1 hr
Lane 5: ab108575, 2 hr
Lane 6: ab108575, 4 hr
Lane 7: ab108575, 8 hr
Lane 8: ab108575, 24 hr -
NIH/3T3 cells were maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin.
When the cells reached confluence, adipogenesis was initiated by adding IBMX, Dexamethasone, and insulin to 0.5mM, 1μM, and 10μg/ml, respectively and continued for 2 days (day 0).
The medium was replaced every 2 days with new medium containing insulin in the presence or absence of 5μg/ml of human Jagged1-Fc (ab108575) and human CD137-Fc as a control-Fc. Staining with Oil Red O was typically performed on day 7
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (2)
ab108575 has been referenced in 2 publications.
- Zhang Y et al. Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1a/Notch pathway in pancreatic ductal adenocarcinoma. Mol Ther Oncolytics 23:51-64 (2021). PubMed: 34632050
- Tang D et al. Notch1 Signaling Contributes to Hypoxia-induced High Expression of Integrin ß1 in Keratinocyte Migration. Sci Rep 7:43926 (2017). PubMed: 28266574